Concepedia

Mark Bresnik

MB

14

Publications

1.3K

Citations

13

H-Index

2005

Active since

Affiliations

Gilead Sciences (United States)(Current)

University of Cologne

University of Washington

Centre Hospitalier Universitaire de Bordeaux

Seattle Children's Hospital

Mark Bresnik is an author at Gilead Sciences (United States) specializing in medicine, clinical microbiology, and antibiotics.

ORCID

Top concepts

Publications per year

2005–2020

14

Publications

14

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)

Oliver A. Cornely, Johan Maertens, Mark Bresnik et al. · Clinical Infectious Diseases · 2007 · 734 citations · Full text

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

B.M. Assael, Tacjana Pressler, Diana Bilton et al. · Journal of Cystic Fibrosis · 2012 · 135 citations

, , +4

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

Oliver A. Cornely, Thibaut Leguay, Johan Maertens et al. · Journal of Antimicrobial Chemotherapy · 2017 · 88 citations · Full text

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

Harm A.W.M. Tiddens, K. De Boeck, John Clancy et al. · Journal of Cystic Fibrosis · 2014 · 60 citations

, , +6

Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease

Oliver A. Cornely, Johan Maertens, Mark Bresnik et al. · Mycoses · 2010 · 58 citations · Full text

Rows per page

1–5 of 14